$VVOS News

Vivos Therapeutics Announces Its Treatment With ITS FDA-Cleared Vida Oral Appliance Demonstrates Enhancement In Insomnia Severity In 100% Of Patients In Trial

Vivos Extends Streeterville Financing Deal Through Aug. 31, Reaffirms Plan To Convert Up To $4.5M Debt Into Preferred And Common Stock

Vivos Therapeutics Announces Intent To File Registration For Proposed Rights Offering

Vivos Therapeutics Partners With South Palm Cardiovascular Associates To Form, Operate Physician-Aligned Management Services Organization AIM Florida

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics Enters Senior Debt-to-Equity Exchange Agreement With Streeterville Capital For Up To $4.5M

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Raises Price Target to $3.1

Vivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic Shifts

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Vivos Therapeutics Q1 EPS $(0.52) Misses $(0.45) Estimate, Sales $5.141M Beat $4.225M Estimate

Ascendiant Capital Maintains Buy on Vivos Therapeutics, Lowers Price Target to $3

New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Group Holding (NASDAQ:YYGH), and Vivos Therapeutics (NASDAQ:VVOS)

HC Wainwright & Co. Maintains Buy on Vivos Therapeutics, Lowers Price Target to $2.5

Vivos Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Vivos Therapeutics shares are trading lower after the company reported worse-than-expected Q4 financial results.

Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...

Vivos Therapeutics Reports Full Year 2025 Financial Results

Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript